Learning objectives:
At the end of this session, the participants should:
-
Understand the results from EINSTEIN JUNIOR that established weight-adjusted dosing and showed the efficacy and reassuring safety profile of rivaroxaban for treatment of VTE in children allowing on-label anticoagulation
-
Confirm consistent benefit in vulnerable populations across indications to ensure optimal pharmaceutical care for anticoagulated patients
-
Know how to use rivaroxaban in vulnerable populations: Babies, children, frail patients, renally impaired patients, patients with cancer or diabetes, and very old patients
Educational needs addressed:
Hospital pharmacists need to have insights into the new pediatric clinical data and the respective new indication of rivaroxaban. Furthermore, hospital pharmacists need to be informed about effective anticoagulation with rivaroxaban across all indications in children and adults, including high-risk vulnerable patients with cardiovascular diseases to ensure optimal pharmaceutical care for anticoagulated patients.
|